0.00Open0.00Pre Close0 Volume0 Open Interest55.00Strike Price0.00Turnover205.69%IV-52.69%PremiumMay 16, 2025Expiry Date18.98Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8902Delta0.0172Gamma1.84Leverage Ratio-0.1182Theta-0.0091Rho-1.64Eff Leverage0.0101Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet